Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.62% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Mar 31, 2024
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-24-000023General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-16.49% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
54.82% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
19.01% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
88.95% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-8.79% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
52.80% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
9.17% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 3.40%
- Current
- 2.62%
- Delta
- -0.78%
- Previous
- 5.70%
- Current
- -16.49%
- Delta
- -22.19%
- Previous
- 76.23%
- Current
- 54.82%
- Delta
- -21.41%
- Previous
- 4.88%
- Current
- 19.01%
- Delta
- 14.14%
- Previous
- 85.33%
- Current
- 88.95%
- Delta
- 3.62%
- Previous
- -15.43%
- Current
- -8.79%
- Delta
- 6.65%
- Previous
- 54.94%
- Current
- 52.80%
- Delta
- -2.14%
- Previous
- 12.12%
- Current
- 9.17%
- Delta
- -2.95%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_DECREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_INCREASED →Transitioned To · ALNY MARGIN_INCREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.